跳至主要内容
临床试验/ISRCTN69163448
ISRCTN69163448已完成不适用

Imaging-based Thrombolysis Trial in Acute Ischemic Stroke

Ministry of Science and Technology of the People's Republic of China (China)0 个研究点目标入组 80 人开始时间: 2005年12月5日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
80

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Age 18-75 years
  • 2. Clinical signs consistent with the diagnosis of ischemic stroke
  • 3. Treatment onset within 3-9 hours after stroke onset
  • 4. No prior neurologic event that would obscure the interpretation of the signal
  • and current presenting neurologic deficits (modified Rankin scale [mRS] =1)
  • 5. National Institutes of Health-Stroke-Scale (NIHSS) score >4 and at least moderate limb weakness
  • 6. MRI screening to be started within 7.5 hours after stroke onset
  • 7. Perfusion abnormality of >2 cm in diameter involving hemispheric gray matter
  • 8. Perfusion/diffusion mismatch of =20
  • 9. Magnetic resonance angiography (MRA) shows that TICI grade is 0 or 1

排除标准

  • 1. Patients not eligible to receive trial treatment within 30-60 min after completion of MRI1
  • 3. Stroke symptoms are rapidly improving by the time of randomization
  • 4. Major stroke symptoms (>25 to 30 on the NIHSS)
  • 5. History of stroke within the previous 6 weeks
  • 6. Seizure at the onset of stroke
  • 7. Stroke due to a neurointerventional procedure for treatment of a cerebral aneurysm and/or cerebral arteriovenous malformation (stroke due to diagnostic cerebral angiography or cardiac catheterization might be treated)
  • 8. Clinical presentation suggestive of subarachnoid hemorrhage, even when the MRI is normal
  • 9. History of intracerebral hemorrhage (ICH) at any time, neoplasm, subarachnoid hemorrhage (SAH), arteriovenous malformation (AVM) or aneurysm
  • 10. Presumed septic embolus
  • 11. Presumed pericarditis related to recent acute myocardial infarction
  • 12. Recent (within 10 to 30 days) surgery, biopsy of a parenchymal organ, or lumbar puncture
  • 13. Recent (within 10 to 30 days) trauma (including head trauma), with internal injuries or ulcerative wounds
  • 14. Known active inflammatory bowel disease, ulcerative colitis, or diverticular disease
  • 15. Any active or recent (within 10 to 30 days) hemorrhage
  • 16. Known hereditary or acquired hemorrhagic diathesis. Baseline laboratory values that reveal platelets are <100 000/µl, hematocrit or platelet cell volume <25 volume %, or oral anticoagulant therapy with an international normalized ratio >1.7.
  • 17. Pregnancy, lactation, or parturition within the previous 30 days
  • 18. Known serious sensitivity to radiographic contrast agents
  • 19. Other serious, advanced, or terminal illness such that life expectancy is <1 year
  • 20. Any other condition that the physician believes would pose a significant hazard to the patient if fibrinolytic therapy were initiated (e.g. amyloid angiopathy)
  • 21. Uncompensated hypertension at study entry or hypertension requiring aggressive treatment to reduce blood pressure to nonhypertensive limits. Uncompensated hypertension is defined as systolic blood pressure >180 mmHg or diastolic blood pressure =105 mmHg on 3 repeated measures at least 10 minutes apart. Aggressive treatment is defined as the need for a continuous, parenteral antihypertensive, such as a nitroprusside drip, or the need to administer >3 doses of a parenteral antihypertensive, such as labetalol or Urapidil.
  • 22. Evidence of ICH or SAH
  • 23. DWI abnormality involving >1/3 of middle cerebral artery (MCA) territory
  • 24. No perfusion deficit
  • 25. Any intracranial pathology interfering with the assessment of diffusion and
  • perfusion abnormalities
  • 26. Contraindications to MRI

研究者

发起方
Ministry of Science and Technology of the People's Republic of China (China)

相似试验